Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prognosis Markers for Monitoring HTLV-1 Neurologic Disease

Full text
Author(s):
Show less -
Prates, Gabriela [1] ; Assone, Tatiane [1] ; Corral, Marcelo [1] ; Baldassin, Maira P. M. [1] ; Mitiko, Tatiane [1] ; Sales, Flavia C. Silva [1] ; Haziot, Michel E. [2] ; Smid, Jerusa [2] ; Fonseca, Luiz A. M. [1] ; Goncalves, Fernanda de Toledo [3] ; Penalva de Oliveira, Augusto C. [2] ; Casseb, Jorge [1]
Total Authors: 12
Affiliation:
[1] Univ Sao Paulo, Fac Med, Sao Paulo - Brazil
[2] Univ Sao Paulo, Inst Infect Dis Emilio Ribas, Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Med FMUSP, Dept Med Legal Etica Med & Med Social & Trabalho, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: NEUROLOGY-CLINICAL PRACTICE; v. 11, n. 2, p. 134-140, APR 2021.
Web of Science Citations: 0
Abstract

Background Human T-cell lymphotropic virus type 1 (HTLV-1) infection is associated not only with some severe manifestations, such as HTLV-1-associated myelopathy (HAM) and ATLL, but also with other, less severe conditions. Some studies have reported neurologic manifestations that did not meet all the criteria for the diagnosis of HAM in individuals infected with HTLV-1; these conditions may later progress to HAM or constitute an intermediate clinical form, between asymptomatic HTLV-1 carriers and those with full myelopathy. This study evaluated the prognostic value and looked for a possible association of those parameters with the intermediate syndrome (IS) status and HAM status. Methods Proviral load (PVL), spontaneous lymphoproliferation, interferon (IFN)-gamma spontaneous production was quantified in samples of asymptomatic and HAM patients, as well as patients with IS. Results The critical age range was 50-60 years for IS outcome and more of 60 years for HAM outcome, with an increased risk of 2.5-fold for IS and 6.8-fold for HAM. IFN-gamma was increased in patients with IS compared with asymptomatic carriers (ACs) (p = 0.007) and in patients with HAM compared with ACs (p = 0.03). Lymphoproliferation was increased in patients with HAM vs ACs (p = 0.0001) and patients with IS (p = 0.0001). PVL was similar between groups. Conclusion IFN-gamma has high specificity of prediction of subject remain asymptomatic compared with PVL and lymphoproliferation assay tests. IFN-gamma has been shown to be a biomarker of progression to intermediate stage and to HAM. The association of other markers with manifestations associated with HTLV-1 infection that does not meet the HAM criteria should be verified. (AU)

FAPESP's process: 16/03025-2 - Identification of polymorphisms related to HTLV-1 associated myelopathy / tropical spastic paraparesis (HAM / TSP)
Grantee:Tatiane Assone Casseb
Support Opportunities: Scholarships in Brazil - Post-Doctoral